Category Archives: Corporate

Latest From Corporate

Insurers Still Spreading Falsehoods To Protect Their Bottom Line

Drugs

For the better part of a year, BIO has been on a mission to shine a light on the insurance industry and what they and their allies do to restrict patient access to innovative breakthroughs. Apparently, we’re not the only ones who’ve caught on to the falsehoods spread by insurers to protect their bottom line. Kaiser Health News’ Chad Terhune says Consumers Union has taken aim at two California Blue Cross Blue Shield insurers who Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

New Study Debunks Myths About Orphan Drug Act and Rare Disease Drug Costs

Be.Futureproof

The Orphan Drug Act has been targeted recently by the insurance industry and its allies in the media, but in the face of withering criticism and unjustified allegations, a new study from IMS Health shows that concerns about rare drug costs are completely misguided. Kaiser Health News’ Sarah Jane Tribble reports the study, published in Health Affairs, “analyzed U.S. pharmaceutical spending from 2007 to 2013 on more than 300 drugs that had orphan approval under Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

BIO Launches New Website Holding Insurers Accountable: Un-surance.com

medical_research

BIO is undertaking an aggressive effort to promote the value of biopharmaceutical innovations and ensure that all patients have access to the drugs they need. A vital component of this campaign is holding insurers and their allies accountable for standing in the way of that access. For months, we’ve blown the whistle on their discriminatory practices, high cost-sharing and cost-shifting, and their blatant falsehoods on what’s driving their premium increases, and today, we’re introducing a Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Latest One-Sided CNBC Interview Repeats Falsehoods, Offers Misleading Statistics

new-bio-logo

I was disappointed by CNBC’s one-sided reporting in an article that repeated numerous falsehoods and misleading statistics that have been previously debunked, apparently based on a single interview with Dr. Kenneth Davis, the President and CEO of Mount Sinai Medical. Unfortunately, this is nothing new. The insurance industry and its allies continue to use the biopharmaceutical industry as a scapegoat for their ever-increasing insurance premiums, deductibles, and co-pays. It’s time to set the record straight. Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Principles Put Patients First

Greenwood_Jim_BTN

Patient advocacy organizations play an indispensable role in the biopharmaceutical development process: They help scientists and researchers better understand what it’s like to live with the diseases they’re trying to cure. That’s why BIO and our member companies are deeply committed to meaningful partnerships with patient advocacy organizations as we work to discover new medications to help patients live longer, healthier, more fulfilling lives. Today, there are more than 250 biotechnology health care medications and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,